Ausgabe 1/2024
Inhalt (15 Artikel)
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification
Guoliang Yao, Jianyong Yuan, Qianqian Duan, Yuan Tan, Qin Zhang, Dongsheng Chen, Jingbo Chen
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide
Kelsey A. Fletcher, Mai H. Alkurashi, Andrew J. Lindsay
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study
Changkun Zhang, Xia You, Qin Zhang, Dong Wang
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Jasmine C. Huynh, May Cho, Arta Monjazeb, Ebaa Al-Obeidi, Amisha Singh, Kit Tam, Frances Lara, Anthony Martinez, Leslie Garcia, Edward J. Kim
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-
Daiki Tsuji, Shigeru Nakagaki, Itsuki Yonezawa, Kenichi Suzuki, Takashi Yokokawa, Yohei Kawasaki, Takumi Yamaguchi, Takashi Kawaguchi, Masahiro Hatori, Takuma Matsumoto, Yukio Sakata, Keisuke Yamamoto, Tomoyasu Nishimura, Yuki Kogure, Toshinobu Hayashi, Misa Osawa, Kunihiko Itoh, Masaya Watanabe
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis
Haibo Lei, Wei Sun, Xiang Liu, Chunjiang Wang
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma
Yanfang Jiang, Xintong Hu, Zhouyu Wang, Qin Zhang, Dongsheng Chen, Pingwei Zhao
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
Yue Wang, Xingyu Lin, Yue Wang, Guan Wang
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects
Hyun Chul Kim, Eunsol Yang, Soyoung Lee, Jaeseong Oh, Myongjae Lee, ChaeEun Lee, Kyoung Soo Ha, Won Sik Lee, In-Jin Jang, Kyung-Sang Yu
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells
Mahtab Afsharzadeh, Jaleh Varshosaz, Mina Mirian, Farshid Hasanzadeh
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function
Jingying Yue, Shuai Shao, Jie Zhou, Wenting Luo, Yanling Xu, Qinbin Zhang, Jing Jiang, Marie M Zhu
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis
Meng-Ting Li, Yang He, Si-Yong Huang, Xiao Hu, Ji-Sheng Chen
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Oluwadunni E. Emiloju, Jun Yin, Emily Koubek, Joel M. Reid, Mitesh J. Borad, Yanyan Lou, Mahesh Seetharam, Martin J. Edelman, Edward A. Sausville, Yixing Jiang, Ahmed O. Kaseb, James A. Posey, Sarah L. Davis, Gregory J. Gores, Lewis R. Roberts, Naoko Takebe, Gary K. Schwartz, Andrea E. Wahner Hendrickson, Scott H. Kaufmann, Alex A. Adjei, Joleen M. Hubbard, Brian A. Costello
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Naoyuki Nogami, Takaaki Tokito, Yoshitaka Zenke, Miyako Satouchi, Takashi Seto, Hideo Saka, Junko Ohtani, Shirong Han, Kazuo Noguchi, Makoto Nishio
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller Jr., Aaron R. Hansen, Jong-Seok Lee, Frank Tsai, Benjamin J. Solomon, Tae Min Kim, Christian Rolfo, Vincent Giranda, Yixin Ren, Fang Liu, Bhargava Kandala, Tomoko Freshwater, Judy S. Wang